(ENOV) Enovis - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 1.447m USD | Total Return: -23.2% in 12m

Orthopedic Implants, Bracing, Bone Stimulators, Physical Therapy
Total Rating 42
Safety 25
Buy Signal -0.22
Medical Devices
Industry Rotation: +4.2
Market Cap: 1.45B
Avg Turnover: 27.0M
Risk 3d forecast
Volatility59.6%
VaR 5th Pctl10.1%
VaR vs Median2.29%
Reward TTM
Sharpe Ratio-0.29
Rel. Str. IBD28.9
Rel. Str. Peer Group55.6
Character TTM
Beta1.568
Beta Downside1.976
Hurst Exponent0.405
Drawdowns 3y
Max DD67.26%
CAGR/Max DD-0.32
CAGR/Mean DD-0.60
EPS (Earnings per Share) EPS (Earnings per Share) of ENOV over the last years for every Quarter: "2021-03": 1.32, "2021-06": 1.68, "2021-09": 1.62, "2021-12": 1.77, "2022-03": 0.37, "2022-06": 0.59, "2022-09": 0.59, "2022-12": 0.72, "2023-03": 0.44, "2023-06": 0.61, "2023-09": 0.56, "2023-12": 0.79, "2024-03": 0.5, "2024-06": 0.62, "2024-09": 0.73, "2024-12": 0.98, "2025-03": 0.81, "2025-06": 0.79, "2025-09": 0.75, "2025-12": 0.95, "2026-03": 0.89,
EPS CAGR: 17.70%
EPS Trend: 96.2%
Last SUE: 3.33
Qual. Beats: 7
Revenue Revenue of ENOV over the last years for every Quarter: 2021-03: 879.211, 2021-06: 356.124, 2021-09: 359.923, 2021-12: 1023.273, 2022-03: 375.457, 2022-06: 395.117, 2022-09: 383.814, 2022-12: 408.713, 2023-03: 406.151, 2023-06: 428.502, 2023-09: 417.524, 2023-12: 455.02, 2024-03: 516.266, 2024-06: 525.16, 2024-09: 505.222, 2024-12: 560.975, 2025-03: 558.834, 2025-06: 564.545, 2025-09: 548.912, 2025-12: 575.758, 2026-03: 589.151,
Rev. CAGR: 14.43%
Rev. Trend: 97.4%
Last SUE: 2.54
Qual. Beats: 1

Warnings

Interest Coverage Ratio -8.6 is critical

Altman Z'' -1.64 < 1.0 - financial distress zone

Choppy

Tailwinds

Pead

Description: ENOV Enovis

Enovis Corporation (ENOV) is a medical technology firm specializing in orthopedic solutions and surgical implants. Following its spin-off from the industrial conglomerate Colfax Corporation, the company operates through two primary segments: Prevention and Recovery and Reconstructive. The business model relies on a multi-channel distribution strategy utilizing direct sales, independent distributors, and direct-to-patient fulfillment.

The Prevention and Recovery segment provides non-invasive products such as bracing, vascular therapy, and electrical stimulators for musculoskeletal conditions. The Reconstructive segment focuses on high-growth surgical markets, including hip, knee, and extremity implants. In the medical device sector, reconstructive surgery companies often benefit from high switching costs for surgeons and favorable demographic trends driven by an aging global population.

For a deeper dive into these fundamentals, ValueRay provides additional data points for your analysis. Enovis maintains a diverse customer base ranging from orthopedic surgeons and physical therapists to athletic trainers, targeting the full continuum of patient care from injury prevention to post-surgical rehabilitation.

Headlines to Watch Out For
  • Reconstructive segment growth accelerates through hip and knee implant market share gains
  • Strategic acquisitions like LimaCorporate drive international scale and revenue diversification
  • High interest rates and debt levels impact earnings per share and valuation
  • Orthopedic surgery volumes fluctuate based on elective procedure demand and hospital staffing
  • New product launches in foot and ankle extremities expand high-margin revenue streams
Piotroski VR‑10 (Strict) 5.0
Net Income: -1.14b TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 1.74 > 1.0
NWC/Revenue: 27.70% < 20% (prev 34.45%; Δ -6.75% < -1%)
CFO/TA 0.06 > 3% & CFO 242.8m > Net Income -1.14b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.04 > 1.5 & < 3
Outstanding Shares: last quarter (56.8m) vs 12m ago 0.0% < -2%
Gross Margin: 56.81% > 18% (prev 0.57%; Δ 5.62k% > 0.5%)
Asset Turnover: 52.33% > 50% (prev 44.11%; Δ 8.23% > 0%)
Interest Coverage Ratio: -8.61 > 6 (EBITDA TTM -192.8m / Interest Expense TTM 56.8m)
Altman Z'' -1.64
A: 0.16 (Total Current Assets 1.24b - Total Current Liabilities 608.7m) / Total Assets 3.83b
B: -0.39 (Retained Earnings -1.48b / Total Assets 3.83b)
C: -0.11 (EBIT TTM -489.1m / Avg Total Assets 4.35b)
D: -0.67 (Book Value of Equity -1.58b / Total Liabilities 2.35b)
Altman-Z'' Score: -1.64 = D
Beneish M -3.51
DSRI: 0.96 (Receivables 444.2m/435.6m, Revenue 2.28b/2.15b)
GMI: 0.99 (GM 56.81% / 56.51%)
AQI: 0.80 (AQ_t 0.52 / AQ_t-1 0.65)
SGI: 1.06 (Revenue 2.28b / 2.15b)
TATA: -0.36 (NI -1.14b - CFO 242.8m) / TA 3.83b)
Beneish M-Score: -3.51 (Cap -4..+1) = AAA
What is the price of ENOV shares? As of May 21, 2026, the stock is trading at USD 26.46 with a total of 459,550 shares traded.
Over the past week, the price has changed by +2.96%, over one month by +0.72%, over three months by +16.41% and over the past year by -23.24%.
Is ENOV a buy, sell or hold? Enovis has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy ENOV.
  • StrongBuy: 7
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the ENOV price?
Analysts Target Price 43 62.5%
Enovis (ENOV) - Fundamental Data Overview as of 19 May 2026
P/E Forward = 7.2046
P/S = 0.6349
P/B = 1.0336
P/EG = 1.8989
Revenue TTM = 2.28b USD
EBIT TTM = -489.1m USD
EBITDA TTM = -192.8m USD
Long Term Debt = 1.26b USD (from longTermDebt, last fiscal year)
Short Term Debt = 60.2m USD (from shortTermDebt, last quarter)
Debt = 1.41b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.38b USD (from netDebt column, last quarter)
Enterprise Value = 2.82b USD (1.45b + Debt 1.41b - CCE 33.1m)
Interest Coverage Ratio = -8.61 (Ebit TTM -489.1m / Interest Expense TTM 56.8m)
EV/FCF = 78.61x (Enterprise Value 2.82b / FCF TTM 35.9m)
FCF Yield = 1.27% (FCF TTM 35.9m / Enterprise Value 2.82b)
FCF Margin = 1.58% (FCF TTM 35.9m / Revenue TTM 2.28b)
Net Margin = -49.91% (Net Income TTM -1.14b / Revenue TTM 2.28b)
Gross Margin = 56.81% ((Revenue TTM 2.28b - Cost of Revenue TTM 983.9m) / Revenue TTM)
Gross Margin QoQ = 54.92% (prev 60.69%)
Tobins Q-Ratio = 0.74 (Enterprise Value 2.82b / Total Assets 3.83b)
Interest Expense / Debt = 1.36% (Interest Expense 19.2m / Debt 1.41b)
Taxrate = 21.0% (US default 21%)
NOPAT = -386.4m (EBIT -489.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.04 (Total Current Assets 1.24b / Total Current Liabilities 608.7m)
Debt / Equity = 0.96 (Debt 1.41b / totalStockholderEquity, last quarter 1.48b)
 Debt / EBITDA = -7.14 (negative EBITDA) (Net Debt 1.38b / EBITDA -192.8m)
 Debt / FCF = 38.34 (Net Debt 1.38b / FCF TTM 35.9m)
Total Stockholder Equity = 1.89b (last 4 quarters mean from totalStockholderEquity)
RoA = -26.12% (Net Income -1.14b / Total Assets 3.83b)
RoE = -60.13% (Net Income TTM -1.14b / Total Stockholder Equity 1.89b)
RoCE = -15.51% (EBIT -489.1m / Capital Employed (Equity 1.89b + L.T.Debt 1.26b))
 RoIC = -11.43% (negative operating profit) (NOPAT -386.4m / Invested Capital 3.38b)
 WACC = 6.35% (E(1.45b)/V(2.86b) * Re(11.50%) + D(1.41b)/V(2.86b) * Rd(1.36%) * (1-Tc(0.21)))
Discount Rate = 11.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 62.99 | Cagr: 1.77%
[DCF] Terminal Value 78.90% ; FCFF base≈35.9m ; Y1≈23.6m ; Y5≈10.8m
 [DCF] Fair Price = N/A (negative equity: EV 308.6m - Net Debt 1.38b = -1.07b; debt exceeds intrinsic value)
 EPS Correlation: 96.19 | EPS CAGR: 17.70% | SUE: 3.33 | # QB: 7
Revenue Correlation: 97.43 | Revenue CAGR: 14.43% | SUE: 2.54 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.85 | Chg30d=-5.88% | Revisions=-64% | Analysts=12
EPS next Quarter (2026-09-30): EPS=0.84 | Chg30d=-0.74% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=3.65 | Chg30d=+1.14% | Revisions=+27% | GrowthEPS=+10.6% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=4.07 | Chg30d=+2.54% | Revisions=+50% | GrowthEPS=+11.5% | GrowthRev=+5.3%
[Analyst] Revisions Ratio: -64%